

The American Journal of Medicine®

PROCEEDINGS OF A SYMPOSIUM

HYPERTENSION, LIPIDS, AND CARDIOVASCULAR DISEASE: IS INSULIN THE MISSING LINK?

VOLUME 90 (2A) FEBRUARY 21, 1991

2A-1S

Introduction

James A. Schoenberger

HYPERTENSION AS A RISK FACTOR

Section Editor: Norman M. Kaplan

2A-2S

Management of Hypertension and Cardiovascular Risk

Norman K. Hollenberg

2A-7S

**Insulin Resistance, Hyperinsulinemia, and Hypertriglyceridemia
in the Etiology and Clinical Course of Hypertension**

Gerald M. Reaven

2A-13S

Hypertension, Endothelium, and Cardiovascular Risk Factors

Leopoldo Raij

2A-19S

**Cardiovascular Risk Reduction: The Role of Antihypertensive
Treatment**

Norman M. Kaplan

2A-21S

**Workshop I—Fifth Joint National Committee Report:
How Should It Differ from the 1988 Report?**

Jerome G. Porush, Myron Weinberger

The American Journal of Medicine®

PROCEEDINGS OF A SYMPOSIUM

HYPERTENSION, LIPIDS, AND CARDIOVASCULAR DISEASE: IS INSULIN THE MISSING LINK?

VOLUME 90 (2A) FEBRUARY 21, 1991

2A-1S

Introduction

James A. Schoenberger

HYPERTENSION AS A RISK FACTOR

Section Editor: Norman M. Kaplan

2A-2S

Management of Hypertension and Cardiovascular Risk

Norman K. Hollenberg

2A-7S

**Insulin Resistance, Hyperinsulinemia, and Hypertriglyceridemia
in the Etiology and Clinical Course of Hypertension**

Gerald M. Reaven

2A-13S

Hypertension, Endothelium, and Cardiovascular Risk Factors

Leopoldo Raij

2A-19S

**Cardiovascular Risk Reduction: The Role of Antihypertensive
Treatment**

Norman M. Kaplan

2A-21S

**Workshop I—Fifth Joint National Committee Report:
How Should It Differ from the 1988 Report?**

Jerome G. Porush, Myron Weinberger

2A-24S

Workshop II—Hypertension Trials and Meta-Analyses: Is There Any Value for Further Studies?

Richard H. Grimm, Jr., Henry Black

2A-26S

Workshop III—Insulin Resistance: Is It Truly the Link?

Joseph L. Izzo, Jr., Arthur L. M. Swislocki

LIPIDS AS A RISK FACTOR

Section Editor: Antonio M. Gotto

2A-32S

The National Cholesterol Education Program: Guidelines, Status, and Issues

DeWitt S. Goodman

2A-36S

The Tangled Web of Coronary Risk Factors

Ronald M. Krauss

2A-42S

Regression of Atherosclerosis: What Does It Mean?

David H. Blankenhorn

2A-48S

Workshop IV—National Cholesterol Education Program Guidelines: Are They Clinically Relevant?

Donald Hunninghake

2A-50S

Workshop V—What Is a Risk Factor and What Is Not—Theoretical and Practical Implications

Thomas A. Pearson

2A-53S

Workshop VI—Regression of Atherosclerosis: What Does It Mean?

B. Greg Brown

INSULIN AS A RISK FACTOR

Section Editor: Ralph A. DeFronzo

2A-56S

Evolving Natural History of Coronary Artery Disease in Diabetes Mellitus

Andrzej S. Krolewski, James H. Warram, Paola Valsania, Blaise C. Martin, Lori M. B. Laffel, A. Richard Christlieb

2A-62S

Insulin as a Mitogenic Factor: Role in the Pathogenesis of Cardiovascular Disease

Robert W. Stout

2A-66S

Diabetic Retinopathy: Can We Modify Its Course?

Lawrence I. Rand

2A-70S

Diabetic Nephropathy: Can the Natural History Be Modified?

Robert G. Narins

2A-76S

Workshop VII—Patient Population and Genetics: Role in

Diabetes

Peter H. Bennett, Michael P. Stern

2A-80S

Workshop VIII—Retinopathy, Nephropathy, Neuropathy, and

Tight Control

Harold E. Lebovitz, Aaron I. Vinik

2A-85S

Workshop IX—Lipids, Insulin, Diabetes

Donald C. Simonson, Victor J. Dzau

2A-87S

Concluding Remarks

James A. Schoenberger

PROCEEDINGS OF A SYMPOSIUM

**THE EUROPEAN WORKING PARTY ON
HIGH BLOOD PRESSURE IN THE ELDERLY**

VOLUME 90 (3A) MARCH 25, 1991

3A-1S

INTRODUCTION

The European Working Party on High Blood Pressure in the Elderly*

Antoon Amery, M.D., André De Schaepdryver, M.D. (*See Appendix, page 3A-3S)

3A-5S

**Trends in Systolic Blood Pressure, 24-Hour Sodium Excretion, and Stroke Mortality
in the Elderly in Belgium**

Jozef V. Joossens, M.D., Hugo Kesteloot, M.D., Ph.D.

3A-12S

**Treatment of Hypertension in the Elderly: Effects on Blood Pressure, Heart Rate,
and Physical Fitness**

Gastone Leonetti, M.D., Carlo Mazzola, M.D., Carlo Pasotti, M.D., Laura Angioni, M.D., Alvaro Vaccarella, M.D., Alberto Capra, M.D., Gianfranco Botta, M.D., Alberto Zanchetti, M.D.

3A-14S

Hypertension and the Risk of Dementia in the Elderly

Françoise Forette, M.D., François Boller, M.D., Ph.D.

3A-20S

**Veterans Administration Cooperative Study Group on Hypertensive Agents: Effects
of Age on Treatment Results**

Edward D. Freis, M.D., for the Veterans Administration Cooperative Study Group on
Antihypertensive Agents

3A-24S**Age-Related Hypotensive Effects of Placebo and Active Treatment in Patients Older Than 60 Years**

Lutgarde Thijs, B.Sc., for the European Working Party on High Blood Pressure in the Elderly* ("See Appendix, page 3A-3S)

3A-27S**Choice of Drug Treatment for Elderly Hypertensive Patients**

Kevin O'Malley, M.D., John P. Cox, M.B., Eoin O'Brien, M.D.

3A-34S**Body Mass Index and Prognosis in Elderly Hypertensive Patients: A Report from the European Working Party on High Blood Pressure in the Elderly**

Jaakko Tuomilehto, M.D., for the European Working Party on High Blood Pressure in the Elderly* ("See Appendix, page 3A-3S.)

3A-42S**Adverse Treatment Effects in the Trial of the European Working Party on High Blood Pressure in the Elderly**

Astrid E. Fletcher, Ph.D., for the European Working Party on High Blood Pressure in the Elderly* ("See Appendix, page 3A-3S.)

3A-45S**Renal Function in the Elderly: Results from the European Working Party on High Blood Pressure in the Elderly Trial**

Peter W. de Leeuw, M.D., for the European Working Party on High Blood Pressure in the Elderly* ("See Appendix, page 3A-3S.)

3A-50S**The Determinants and Prognostic Significance of Serum Uric Acid in Elderly Patients of the European Working Party on High Blood Pressure in the Elderly Trial**

Jan Staessen, M.D., Ph.D., for the European Working Party on High Blood Pressure in the Elderly* ("See Appendix, page 3A-3S.)

3A-55S**Left Ventricular Hypertrophy in Elderly Hypertensive Patients: A Report from the European Working Party on High Blood Pressure in the Elderly Trial**

Roger Van Hoof, M.D., for the European Working Party on High Blood Pressure in the Elderly* ("See Appendix, page 3A-3S.)

3A-60S**Mortality and Treated Blood Pressure in Patients of the European Working Party on High Blood Pressure in the Elderly**

Jan Staessen, M.D., Ph.D., for the European Working Party on High Blood Pressure in the Elderly* ("See Appendix, page 3A-3S.)

3A-62S**Serum Cholesterol Levels and Survival in Elderly Hypertensive Patients: Analysis of Data from the European Working Party on High Blood Pressure in the Elderly**

Robert Fagard, M.D., for the European Working Party on High Blood Pressure in the Elderly* ("See Appendix, page 3A-3S.)

3A-64S**Isolated Systolic Hypertension in the Elderly: An Epidemiologic Review**

Antoon Amery, M.D., Robert Fagard, M.D., C. Guo, M.D., Jan Staessen, M.D., Ph.D., Lutgarde Thijs, B.Sc.

ADDENDA

The European Working Party on High Blood Pressure in the Elderly (EWPHE): An International Trial of Antihypertensive Therapy in Elderly Patients. Objectives, Protocol and Organization

(Reprinted with permission from Arch Int Pharmacodyn Ther 1985; 275: 300-334)

Mortality and Morbidity Results from the European Working Party on High Blood Pressure in the Elderly Trial

Antoon Amery, M.D., Willem H. Birkenhäger, M.D., Peter Brixko, M.D., *et al.* (Reprinted with permission from Lancet 1985; 1: 1349-1354)

Efficacy of Antihypertensive Drug Treatment According to Age, Sex, Blood Pressure, and Previous Cardiovascular Disease in Patients Over the Age of 60

Antoon Amery, M.D., Willem H. Birkenhäger, M.D., Peter Brixko, M.D., *et al.* (Reprinted with permission from Lancet 1986; 2: 589-592)

PROCEEDINGS OF A SYMPOSIUM

THE CHALLENGE OF COMBINATION ANTIRETROVIRAL THERAPY

VOLUME 90 (4A) APRIL 10, 1991

4A-1S

The Challenge of Combination Antiretroviral Therapy for AIDS: An Introduction

Jerome E. Groopman

4A-2S

Antiretroviral Therapy in Combination with Interferon for AIDS-Related Kaposi's Sarcoma

Margaret A. Fischl

4A-8S

Treatment of AIDS with Combinations of Antiretroviral Agents

Thomas C. Merigan

4A-18S

Antiretroviral Therapy and Immunomodulators in Patients with AIDS

Jerome E. Groopman

4A-22S

Relative Resistance of Primary HIV-1 Isolates to Neutralization by Soluble CD4

Eric S. Daar, David D. Ho

4A-27S

Treatment of AIDS with Combinations of Antiretroviral Agents: A Summary

Jerome E. Groopman

PROCEEDINGS OF A SYMPOSIUM

**HYPERTENSION IN AN AGING POPULATION:
PROBLEMS AND OPPORTUNITIES**

VOLUME 90 (4B) APRIL 25, 1991

4B-1S

Hypertension in an Aging Population: Problems and Opportunities

Norman K. Hollenberg

4B-3S

Epidemiology and Evaluation: Steps Toward Hypertension Treatment in the 1990s

James A. Schoenberger

4B-8S

Vascular Injury: Mechanisms and Manifestations

Winifred G. Nayler

4B-14S

Epidemiology, Pathophysiology, and Management of Isolated Systolic Hypertension in the Elderly

William H. Frishman

4B-21S

The Aging Hypertensive Kidney: Pathophysiology and Therapeutic Options

John H. Bauer, Garry P. Reams, Zhen Wu

4B-28S

Practical Considerations in Treating the Elderly Hypertensive Patient

James F. Burris

PROCEEDINGS OF A SYMPOSIUM

**CALCIUM ANTAGONISTS:
CURRENT USE AND FUTURE IMPLICATIONS**

VOLUME 90 (5A) MAY 17, 1991

5A-1S

Introduction

Franz H. Messerli

5A-3S

Impact of Age, Race, and Obesity on Hypertensive Mechanisms and Therapy

Matthew R. Weir

5A-15S

The Relationship of Sodium Balance and Concomitant Diuretic Therapy to Blood Pressure Response with Calcium Channel Entry Blockers

Myron H. Weinberger

5A-21S

Role of Calcium Channel Blockers in Protection Against Experimental Renal Injury

Robert W. Schrier

5A-27S

Left Ventricular Hypertrophy: Impact of Calcium Channel Blocker Therapy

Franz H. Messerli

5A-32S

Therapeutic Benefits of Calcium Channel Blockers in Cyclosporine-Treated Organ Transplant Recipients: Blood Pressure Control and Immunosuppression

Matthew R. Weir

5A-37S

Improvement of Cadaver Renal Transplantation Outcomes with Verapamil: A Review

Ingemar Dawidson, Pal Rooth

5A-42S

Nonsteroidal Anti-Inflammatory Drugs and Antihypertensives

Mark C. Houston

5A-48S

Verapamil and Migraine Prophylaxis: Mechanisms and Efficacy

Herbert G. Markley

